XML 71 R65.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Information - Summary of significant segment expenses and segment net loss (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2025
Jun. 30, 2025
Mar. 31, 2025
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Sep. 30, 2025
Sep. 30, 2024
Dec. 31, 2024
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]                  
Canvuparatide direct program expense $ 10,130     $ 5,957     $ 27,390 $ 14,920  
MBX 4291 direct program expense 2,669     5,514     10,991 7,659  
Imapextide direct program expense 618     2,066     3,411 9,810  
Preclinical and other research and development direct expense 1,466     194     4,316 769  
Research and development overhead expense 4,387     3,016     13,292 9,034  
Other segment items [1] 2,348     1,395     5,509 4,144  
Net loss $ 21,618 $ 19,411 $ 23,880 $ 18,142 $ 15,857 $ 12,337 $ 64,909 $ 46,336 $ 61,900
[1]

(1) Other segment items are primarily comprised of general and administrative expenses and interest and other income.